Overcoming STI571 resistance with the famesyl transferase inhibitor SCH66336

Blood

Volumn 100, Issue 3, 2002, Pages 1068-1071

  Hoover, Russell R ^a,b,c   Manon, Francois Xavier ^a,b,c   Melo, Junia V ^a,b,c   Daley, George Q ^a,b,c  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; LONAFARNIB;

APOPTOSIS; ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036683409     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.3.1068     Document Type: Article

References (18)

1. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
2. Roots of clinical resistance to STI-571 cancer therapy
3. Roots of clinical resistance to STI-571 cancer therapy
4. Induction of resistance to the Abelson inhibitor STi571 in human leukemic cells through gene amplification
5. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
6. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
7. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
8. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia
9. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML
10. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression
11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
12. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase chronic myeloid leukemia
13. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
14. Isotype-specific ras GTP levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of ras mutational status
15. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in p190 transgenic mice with the farnesyl transferase inhibitor SCH66336
16. Activity of the farnesyl transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from CML patients
17. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
18. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial